Showing results (161-170 of 183) with videos related to
Sort By:
Pageof 19
Lancet (London, England)|April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsPaul E Sax, David Wohl, Michael T Yin, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2009
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJosep Mallolas, Daniel Podzamczer, Ana Milinkovic, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2009
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed PatientsDaniel Podzamczer, Montserrat Olmo, Jose Sanz, et al.Neurology|June 8, 2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditionsEllen C Caniglia, Lauren E Cain, Amy Justice, et al.AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 29, 2021
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network CohortJuan Berenguer, Cristina Díez, María Martín-Vicente, et al.The Lancet. Infectious Diseases|October 13, 2011
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, , Dominique Costagliola, et al.Enfermedades Infecciosas Y Microbiologia Clinica|January 31, 2007
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]Ana María Caro-Murillo, Jesús Castilla, Santiago Pérez-Hoyos, et al.Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.Pageof 19